The National Institutes of Health has launched the Long-Acting Therapy to Improve Treatment Success in Daily Life (LATITUDE) study, which compares monthly injectable antiretroviral therapy to daily oral drugs in people unable to adhere to strict daily regimens. The trial is funded by the National Institute of Allergy and Infectious and will be conducted by the AIDS Clinical Trials Group with support from the National Institute of Mental Health, the National Institute on Drug Abuse, ViiV Healthcare, and the Janssen Pharmaceutical Companies of Johnson & Johnson.
The trial will evaluate two experimental, long-acting injections of the antiretroviral drugs rilpivirine and cabotegravir, which will be administered every four weeks by a healthcare professional in a research clinic. Throughout the study, investigators will evaluate volunteers’ viral load—the measure of virus in the blood—and other indicators of immune health to compare the treatment’s effectiveness to that of conventional oral ART.
Learn more about the study.
